Anti-Parkinson Drugs Global Market Report 2022 – Yahoo Finance

Check back at 8:30 a.m. ET for results
Major players in the anti-Parkinson drugs market are GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S. A, Teva Pharmaceuticals, AbbVie Inc. , Mylan, Boehringer Ingelheim, Orion Pharma, ACADIA Pharmaceuticals Inc, Sun Pharma, Wockhardt, Dr.
New York, March 16, 2022 (GLOBE NEWSWIRE) — announces the release of the report "Anti-Parkinson Drugs Global Market Report 2022" –
Reddy’s, Intas, US WorldMeds, Zydus Cadila, Cipla, Strides, 1 A Pharma, Upsher-Smith, Lundbeck, Vertical Pharmaceuticals, LLC, Zambon Pharmaceuticals, M Somerset Pharmaceuticals Inc., and Wockhardt.

The global anti-parkinson drugs market is expected to grow from $8.86 billion in 2021 to $9.56 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $12.25 billion in 2026 at a CAGR of 6.4%.

The anti-Parkinson drugs market consists of sales of drugs used for treating Parkinson’s disease (PD), generated by the establishments that manufacture these drugs.Parkinson’s disease is a neurodegenerative disorder that affects predominately dopaminergic neurons in a specific area of the brain named substantia nigra and disturbs the movement of the body.

People suffering from PD may experience tremor, bradykinesia, limb rigidity, gait, and balance problems.

The main class of anti-Parkinson drugs are levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type b (MAO-b) inhibitors, catechol-o-methyltransferase (COMT)-inhibitors, anticholinergics and other drugs.catechol-O-methyltransferase (COMT) inhibitors are a class of drugs used to treat Parkinson’s disease symptoms in conjunction with carbidopa-levodopa therapy. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered through oral, injection, and transdermal that are distributed through hospital pharmacies, retail pharmacies and online pharmacies.

North America was the largest region in the anti-Parkinson drugs market in 2021.Middle East is expected to be the fargest growing region in the forecast period.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The increasing geriatric population and surging cases of Parkinson’s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market.PD commonly occurs in people over the age of 60 years.

According to the United Nations Department of Economic and Social Affairs, one in 11 people in the world was over the age of 65 in 2019 and this number is expected to increase to one in six people by the end of 2050.Furthermore, according to the Michael J.

Fox Foundation for Parkinson’s Research’s statistics published in June 2019, over 1 million Americans live with PD. Degeneration of neurons in the geriatric population and the surge in cases of Parkinson’s disease is therefore driving the market growth.

Increasing investments by governments and companies for Parkinson’s disease drug R&D is a major trend in the anti-Parkinson drugs market.For instance, according to the report published by the Parkinson’s Foundation, the foundation awarded $6 million to Parkinson’s disease (PD) research.

In January 2019, Parkinson’s UK Research and Support charity in the United Kingdom announced a research investment of $1.9 million (£1.5 million) into its drug discovery program to develop novel gene transcription modulators for Parkinson’s disease. Hence, increasing investments in Parkinson’s drug development are expected to drive the anti-Parkinson’s drugs market.

The high cost of Parkinson’s disease treatment is anticipated to limit the growth of anti-Parkinson’s drugs market over the forecast period.According to the Michael J.

Fox Foundation for Parkinson’s Research’s statistics published in June 2019, the economic burden of Parkinson’s disease on patients, families, and the federal governments is increasing. In the United States, the overall cost of Parkinson’s disease to individuals, families, and government is $51.9 billion annually, with $25.4 billion on direct medical costs (including hospitalization and medication). Thus, the high cost of Parkinson’s disease treatment is expected to impact the anti-Parkinson drugs market.

In June 2019, AbbVie Inc., a global research-driven biopharmaceutical company, announced the acquisition of Allergan plc, a Dublin-based pharmaceutical company, for an amount of $63 billion. With Allergan’s diversified product portfolio, AbbVie expected to strengthen the company’s position in international biopharmaceutical markets. AbbVie Inc. invested in neuroscience, multiple sclerosis, Alzheimer’s disease, and investigating potential disease for Parkinson’s disease. Allergan plc is a pharmaceutical company engaged in developing, manufacturing, and commercializing branded pharmaceutical, biologic, surgical, device, and regenerative medicine products for patients worldwide.

The countries covered in the anti-Parkinson drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


Shares of Incannex Healthcare (NASDAQ: IXHL) were crashing 58.4% lower as of 3:52 p.m. ET on Wednesday. The huge decline came after the Australian drugmaker announced earlier today the issuance of 1.85 million shares related to the exercise of unlisted stock options. The addition of 1.85 million shares makes up less than 4% of Incannex Healthcare's outstanding shares.
Because, unfortunately, nature does not cure disease, even though the words of French philosopher and historian Voltaire would have you believe otherwise: "The art of medicine consists of amusing the patient while nature cures the disease," Voltaire had once famously said. TheStreet has compiled a list of some of the most expensive drug treatments in the world that cure diseases ranging from progeria, when infants start to look elderly to spinal muscular atrophy, neuroblastoma and a rare blood disorder. Swiss pharmaceutical giant Novartis apparently sells the most expensive drug in the world that costs $2.1 million.
Pfizer and its partner BioNTech asked U.S. regulators Tuesday to authorize an additional booster dose of their COVID-19 vaccine for seniors, saying data from Israel suggests older adults would benefit. Currently the U.S. urges two primary shots followed months later by a booster dose for everyone age 12 and older. The Food and Drug Administration and the Centers for Disease Control would have to approve the request.
When most companies spotlight record revenue growth, that means they’ve sold more product than ever before. But for pharmaceutical companies, that isn’t necessarily the case.
Apellis said Wednesday it plans to ask the FDA to approve its eye-disease treatment in the second quarter, and APLS stock surged.
Health insurers that sell private Medicare plans collected $12 billion more caring for seniors in 2020 than it would have cost in traditional Medicare, according to a report from the Medicare Payment Advisory Commission.It shows the need for major payment reforms, according to the report.Get market news worthy of your time with Axios Markets. Subscribe for free.Why it matters: Overpaying the Medicare Advantage plans as their enrollment continues to grow threatens Medicare's long-term finances.De
Patients who received Biogen's Alzheimer's drug for over two years showed slower cognitive decline — leading Biogen stock to tick higher.
The research will focus on treating a recurrence of prostate cancer, for which there is just a 29% survival rate
Shares of Biogen Inc. gained 4.3% in premarket trading on Wednesday after the company announced new data for its Alzheimer's disease drug demonstrating reductions in amyloid beta plaques for 132 weeks and plasma p-tau181 for 128 weeks. The company also said in a news release that the clinical-trial data show that patients with lower plasma p-tau181 levels had less clinical decline. Adoption of Aduhelm has been low since it was approved in June. The drug generated $3 million in the six months of
As most start to restart daily life, experts worry COVID-19 may not be done yet and one company says a fourth shot may be needed.
The disinfectant is commonly used to clean fish tanks
Vladimir Putin’s mental state is “normal”, the Kremlin insisted on Wednesday, amid rumours that the Russian president may be suffering from an illness or even an addiction to steroids.
Health care stocks represent the only defensive sector that is also relatively immune to inflationary risks.
At age 37, Robert Valencia weighed 330 pounds. He tells Men's Health how he lost 150 pounds and lowered his body fat after committing to a healthy lifestyle.
Just as mandates end and more people are taking off their masks, another COVID variant is spreading, causing cases to rise around the world.
WRTV's Nikki DeMentri shows us why early detection is important when diagnosing Alzheimer's and dementia.
"I always felt like I had something to prove."
Shares of Apellis Pharmaceuticals Inc. gained 6.1% in premarket trading on Wednesday after the company shared longer-term clinical data demonstrating that intravitreal pegcetacoplan reduced geographic atrophy lesion growth at 18 months. The data, culled from two clinical trials, will be used in the new drug application that is expected to be submitted to the Food and Drug Administration in the second quarter of this year. The study's investigator said in a news release that the data shows the in
‘I’m not sure people appreciate quite how bad the Covid situation is in Hong Kong, nor what might be around the corner’
Wastewater samples — which can predict when COVID-19 infections will increase — show that U.S. cases are rising again


Add a Comment

Your email address will not be published. Required fields are marked *